TCGA-49-AARQ-01A-11R-A41B-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 41
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.360
- PANCREAS_BETA_CELLS+0.330
- SPERMATOGENESIS+0.240
- INTERFERON_ALPHA_RESPONSE+0.220
- APICAL_SURFACE+0.170
- INTERFERON_GAMMA_RESPONSE+0.140
- ALLOGRAFT_REJECTION+0.060
- MYOGENESIS+0.030
- BILE_ACID_METABOLISM+0.010
- XENOBIOTIC_METABOLISM-0.020
Top 10 suppressed
- TGF_BETA_SIGNALING-0.620
- MYC_TARGETS_V1-0.580
- UNFOLDED_PROTEIN_RESPONSE-0.550
- PROTEIN_SECRETION-0.520
- MYC_TARGETS_V2-0.490
- ANDROGEN_RESPONSE-0.480
- MITOTIC_SPINDLE-0.440
- WNT_BETA_CATENIN_SIGNALING-0.420
- UV_RESPONSE_DN-0.400
- ANGIOGENESIS-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-49-AAR2-01A-11R-A39D-07 | — | cohortA3 | 0.923 |
| 2 | MNG339 | — | — | 0.920 |
| 3 | SRR8942987 | — | — | 0.919 |
| 4 | SRR8392892 | — | cohortA1 | 0.918 |
| 5 | SRR12202406 | — | — | 0.916 |
| 6 | SRR8942994 | — | — | 0.915 |
| 7 | MDT-AP-1327 | Med | Medulloblastoma | 0.909 |
| 8 | MNG1156 | — | — | 0.909 |
| 9 | SRR33346946 | — | — | 0.905 |
| 10 | SRR13311156 | — | — | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.140 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.060 | Idelalisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |